| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anorexia Nervosa | 128 | 2023 | 1286 | 18.840 |
Why?
|
| Bone Density | 107 | 2022 | 3468 | 6.740 |
Why?
|
| Human Growth Hormone | 64 | 2020 | 683 | 6.600 |
Why?
|
| Pituitary Neoplasms | 84 | 2020 | 1345 | 6.160 |
Why?
|
| Acromegaly | 41 | 2020 | 347 | 4.350 |
Why?
|
| Bone and Bones | 46 | 2022 | 2576 | 4.060 |
Why?
|
| Insulin-Like Growth Factor I | 73 | 2021 | 2016 | 3.790 |
Why?
|
| Body Composition | 68 | 2019 | 2402 | 3.400 |
Why?
|
| Adenoma | 59 | 2018 | 2174 | 3.320 |
Why?
|
| Hyperprolactinemia | 19 | 2018 | 129 | 3.010 |
Why?
|
| Bone Diseases, Metabolic | 19 | 2019 | 417 | 2.990 |
Why?
|
| Amenorrhea | 32 | 2021 | 485 | 2.800 |
Why?
|
| Adipose Tissue | 36 | 2022 | 3280 | 2.780 |
Why?
|
| Hypopituitarism | 18 | 2017 | 254 | 2.720 |
Why?
|
| Hydrocortisone | 40 | 2020 | 1826 | 2.670 |
Why?
|
| Bone Marrow | 17 | 2022 | 2948 | 2.380 |
Why?
|
| Testosterone | 42 | 2019 | 2419 | 2.290 |
Why?
|
| Pituitary Gland | 23 | 2017 | 665 | 2.280 |
Why?
|
| Hypothalamo-Hypophyseal System | 14 | 2017 | 703 | 2.210 |
Why?
|
| Growth Hormone | 27 | 2016 | 705 | 2.070 |
Why?
|
| Prolactinoma | 13 | 2016 | 113 | 1.940 |
Why?
|
| Absorptiometry, Photon | 47 | 2022 | 1725 | 1.780 |
Why?
|
| Dopamine Agonists | 11 | 2018 | 355 | 1.770 |
Why?
|
| Pituitary-Adrenal System | 11 | 2017 | 553 | 1.770 |
Why?
|
| Osteoporosis | 22 | 2017 | 1579 | 1.690 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2013 | 1677 | 1.630 |
Why?
|
| Fasting | 17 | 2023 | 1592 | 1.540 |
Why?
|
| Estradiol | 34 | 2022 | 2020 | 1.530 |
Why?
|
| Proteins | 18 | 2014 | 6100 | 1.510 |
Why?
|
| Hypogonadism | 24 | 2015 | 799 | 1.460 |
Why?
|
| Prolactin | 32 | 2014 | 669 | 1.460 |
Why?
|
| Ghrelin | 17 | 2018 | 266 | 1.450 |
Why?
|
| Oxytocin | 8 | 2023 | 394 | 1.440 |
Why?
|
| Cushing Syndrome | 14 | 2020 | 249 | 1.430 |
Why?
|
| Peptide YY | 11 | 2015 | 130 | 1.370 |
Why?
|
| Leptin | 25 | 2018 | 1600 | 1.310 |
Why?
|
| Endocrine System | 4 | 2017 | 113 | 1.280 |
Why?
|
| Androgens | 9 | 2011 | 1281 | 1.270 |
Why?
|
| HIV Wasting Syndrome | 10 | 2001 | 97 | 1.260 |
Why?
|
| Peptide Hormones | 9 | 2006 | 134 | 1.250 |
Why?
|
| Menstruation | 8 | 2019 | 302 | 1.240 |
Why?
|
| Somatostatin | 13 | 2018 | 459 | 1.220 |
Why?
|
| Appetite | 8 | 2021 | 243 | 1.220 |
Why?
|
| Hormone Replacement Therapy | 10 | 2017 | 745 | 1.180 |
Why?
|
| RNA, Untranslated | 5 | 2012 | 453 | 1.160 |
Why?
|
| Hormones | 14 | 2015 | 889 | 1.110 |
Why?
|
| Weight Gain | 14 | 2018 | 2293 | 1.080 |
Why?
|
| Bone Remodeling | 13 | 2021 | 575 | 1.050 |
Why?
|
| Adrenocorticotropic Hormone | 18 | 2016 | 648 | 1.050 |
Why?
|
| Estrogen Replacement Therapy | 9 | 2021 | 1203 | 1.050 |
Why?
|
| Body Weight | 25 | 2017 | 4671 | 1.040 |
Why?
|
| Hypothalamic Diseases | 8 | 2012 | 135 | 1.010 |
Why?
|
| Adult | 257 | 2022 | 214052 | 1.010 |
Why?
|
| Adolescent | 126 | 2022 | 85779 | 1.010 |
Why?
|
| Finite Element Analysis | 8 | 2019 | 431 | 0.980 |
Why?
|
| Female | 299 | 2023 | 380193 | 0.970 |
Why?
|
| Adipose Tissue, Brown | 4 | 2014 | 756 | 0.940 |
Why?
|
| Humans | 414 | 2023 | 744366 | 0.920 |
Why?
|
| Genomic Imprinting | 5 | 2019 | 328 | 0.910 |
Why?
|
| Pituitary ACTH Hypersecretion | 8 | 2018 | 175 | 0.860 |
Why?
|
| Diabetes Insipidus | 3 | 2015 | 151 | 0.820 |
Why?
|
| Hypothalamus | 11 | 2017 | 1063 | 0.810 |
Why?
|
| Estrogens | 14 | 2022 | 1566 | 0.800 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 4 | 2013 | 76 | 0.780 |
Why?
|
| Genes, Tumor Suppressor | 4 | 2015 | 1097 | 0.780 |
Why?
|
| Body Mass Index | 37 | 2019 | 12721 | 0.780 |
Why?
|
| Postprandial Period | 6 | 2019 | 292 | 0.750 |
Why?
|
| Radius | 12 | 2021 | 422 | 0.730 |
Why?
|
| Fibroblast Growth Factors | 4 | 2015 | 878 | 0.730 |
Why?
|
| Bone Development | 4 | 2013 | 483 | 0.730 |
Why?
|
| Intra-Abdominal Fat | 6 | 2017 | 591 | 0.730 |
Why?
|
| Membrane Proteins | 7 | 2015 | 7882 | 0.730 |
Why?
|
| Fractures, Bone | 9 | 2022 | 1947 | 0.720 |
Why?
|
| Adolescent Development | 3 | 2013 | 279 | 0.720 |
Why?
|
| Tumor Suppressor Protein p53 | 9 | 2021 | 2949 | 0.720 |
Why?
|
| Ergolines | 4 | 2014 | 61 | 0.700 |
Why?
|
| Osteogenesis | 6 | 2014 | 1299 | 0.700 |
Why?
|
| Reference Values | 27 | 2019 | 4982 | 0.700 |
Why?
|
| Octreotide | 9 | 2017 | 145 | 0.690 |
Why?
|
| Sex Characteristics | 10 | 2019 | 2585 | 0.680 |
Why?
|
| Endocrine System Diseases | 7 | 2017 | 248 | 0.680 |
Why?
|
| Cross-Sectional Studies | 51 | 2023 | 25039 | 0.670 |
Why?
|
| Lumbar Vertebrae | 14 | 2021 | 1848 | 0.660 |
Why?
|
| Tibia | 7 | 2022 | 1077 | 0.660 |
Why?
|
| Malnutrition | 4 | 2014 | 625 | 0.650 |
Why?
|
| Young Adult | 67 | 2022 | 56429 | 0.640 |
Why?
|
| Inhibins | 6 | 2000 | 211 | 0.640 |
Why?
|
| Etidronic Acid | 2 | 2011 | 64 | 0.640 |
Why?
|
| Pituitary Diseases | 6 | 2017 | 141 | 0.620 |
Why?
|
| Bone Density Conservation Agents | 4 | 2014 | 772 | 0.610 |
Why?
|
| Thyrotropin | 14 | 2013 | 849 | 0.600 |
Why?
|
| Activins | 7 | 2004 | 208 | 0.590 |
Why?
|
| Bone Resorption | 8 | 2014 | 723 | 0.590 |
Why?
|
| Feeding Behavior | 6 | 2019 | 3188 | 0.580 |
Why?
|
| Case-Control Studies | 37 | 2019 | 21748 | 0.580 |
Why?
|
| Middle Aged | 159 | 2020 | 213390 | 0.580 |
Why?
|
| Calcium-Binding Proteins | 9 | 2019 | 1081 | 0.560 |
Why?
|
| Anorexia | 2 | 2014 | 161 | 0.560 |
Why?
|
| Adiposity | 6 | 2019 | 1806 | 0.550 |
Why?
|
| Gene Expression | 9 | 2012 | 7798 | 0.550 |
Why?
|
| Obesity | 20 | 2019 | 12746 | 0.550 |
Why?
|
| Spine | 13 | 2019 | 1144 | 0.550 |
Why?
|
| Femur | 6 | 2014 | 1297 | 0.540 |
Why?
|
| Energy Intake | 7 | 2018 | 2148 | 0.540 |
Why?
|
| Receptors, Somatotropin | 5 | 2020 | 76 | 0.530 |
Why?
|
| Radioimmunoassay | 13 | 2010 | 919 | 0.530 |
Why?
|
| Ethinyl Estradiol | 4 | 2018 | 116 | 0.520 |
Why?
|
| Pituitary Hormones | 6 | 2013 | 183 | 0.520 |
Why?
|
| Menopause | 10 | 2019 | 1626 | 0.510 |
Why?
|
| Dehydroepiandrosterone Sulfate | 4 | 2009 | 238 | 0.510 |
Why?
|
| Norethindrone | 3 | 2004 | 59 | 0.500 |
Why?
|
| Anxiety | 8 | 2019 | 4293 | 0.500 |
Why?
|
| Pituitary Gland, Anterior | 7 | 2010 | 177 | 0.490 |
Why?
|
| Male | 171 | 2021 | 350115 | 0.480 |
Why?
|
| Bone Diseases | 4 | 2013 | 416 | 0.470 |
Why?
|
| Amygdala | 6 | 2017 | 1315 | 0.470 |
Why?
|
| Hypothalamic Hormones | 4 | 2013 | 147 | 0.470 |
Why?
|
| Recombinant Proteins | 14 | 2021 | 6621 | 0.470 |
Why?
|
| Promoter Regions, Genetic | 8 | 2010 | 5867 | 0.470 |
Why?
|
| Cold Temperature | 3 | 2015 | 772 | 0.450 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 894 | 0.440 |
Why?
|
| Follicle Stimulating Hormone | 18 | 1995 | 744 | 0.440 |
Why?
|
| RNA, Messenger | 20 | 2007 | 13035 | 0.440 |
Why?
|
| Gonadotropins, Pituitary | 6 | 2002 | 73 | 0.440 |
Why?
|
| Teriparatide | 2 | 2014 | 225 | 0.440 |
Why?
|
| Cardiovascular Diseases | 15 | 2013 | 15160 | 0.440 |
Why?
|
| Glycoproteins | 9 | 2003 | 2266 | 0.440 |
Why?
|
| Hunger | 3 | 2019 | 198 | 0.430 |
Why?
|
| Receptors, Growth Factor | 5 | 2000 | 334 | 0.420 |
Why?
|
| Prefrontal Cortex | 6 | 2017 | 2147 | 0.420 |
Why?
|
| Gene Silencing | 4 | 2012 | 1539 | 0.420 |
Why?
|
| Oligopeptides | 1 | 2018 | 1189 | 0.420 |
Why?
|
| Receptors, Somatostatin | 4 | 2020 | 129 | 0.410 |
Why?
|
| Impulsive Behavior | 1 | 2014 | 316 | 0.410 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 11 | 1993 | 98 | 0.400 |
Why?
|
| Glucose | 7 | 2018 | 4398 | 0.390 |
Why?
|
| DNA Methylation | 6 | 2019 | 4285 | 0.390 |
Why?
|
| Collagen Type I | 6 | 2013 | 592 | 0.380 |
Why?
|
| Postmenopause | 4 | 2017 | 2460 | 0.380 |
Why?
|
| Cysts | 1 | 2016 | 678 | 0.380 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2010 | 31 | 0.380 |
Why?
|
| Nutritional Status | 11 | 2005 | 1609 | 0.380 |
Why?
|
| Heart Valves | 2 | 2010 | 291 | 0.380 |
Why?
|
| Gene Expression Regulation | 4 | 2013 | 12073 | 0.370 |
Why?
|
| Gonadotropin-Releasing Hormone | 16 | 1996 | 1206 | 0.360 |
Why?
|
| Depression | 7 | 2019 | 7759 | 0.360 |
Why?
|
| Cell Division | 6 | 2003 | 4569 | 0.360 |
Why?
|
| Peptides, Cyclic | 4 | 2016 | 400 | 0.360 |
Why?
|
| Pregnancy Complications, Neoplastic | 3 | 2010 | 255 | 0.350 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 705 | 0.350 |
Why?
|
| Hip | 3 | 2017 | 257 | 0.350 |
Why?
|
| Drug Resistance | 3 | 2017 | 1608 | 0.350 |
Why?
|
| Body Dysmorphic Disorders | 1 | 2013 | 229 | 0.350 |
Why?
|
| Luteinizing Hormone | 19 | 1995 | 869 | 0.350 |
Why?
|
| Progesterone | 7 | 2019 | 775 | 0.350 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 4 | 2020 | 45 | 0.340 |
Why?
|
| Procollagen | 5 | 2013 | 185 | 0.340 |
Why?
|
| Dietary Fats | 4 | 2017 | 2016 | 0.340 |
Why?
|
| Regression Analysis | 17 | 2014 | 6459 | 0.340 |
Why?
|
| Food | 5 | 2021 | 772 | 0.340 |
Why?
|
| Hemangiopericytoma | 1 | 2009 | 77 | 0.330 |
Why?
|
| Overweight | 4 | 2017 | 2371 | 0.330 |
Why?
|
| Bone Marrow Cells | 2 | 2015 | 2513 | 0.330 |
Why?
|
| Child | 40 | 2019 | 77709 | 0.320 |
Why?
|
| Neurosecretory Systems | 1 | 2009 | 231 | 0.320 |
Why?
|
| Pregnanolone | 2 | 2019 | 62 | 0.320 |
Why?
|
| Blood Glucose | 18 | 2018 | 6254 | 0.320 |
Why?
|
| Thinness | 3 | 2017 | 480 | 0.320 |
Why?
|
| Hip Joint | 2 | 2013 | 1002 | 0.320 |
Why?
|
| Growth Disorders | 3 | 2019 | 645 | 0.310 |
Why?
|
| DNA, Intergenic | 1 | 2008 | 107 | 0.310 |
Why?
|
| Body Height | 4 | 2008 | 1578 | 0.310 |
Why?
|
| Depressive Disorder, Major | 10 | 2018 | 4639 | 0.310 |
Why?
|
| Double-Blind Method | 16 | 2021 | 12025 | 0.310 |
Why?
|
| Insulin | 12 | 2010 | 6582 | 0.300 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2009 | 272 | 0.300 |
Why?
|
| Pituitary Hormones, Anterior | 7 | 1991 | 65 | 0.300 |
Why?
|
| Dietary Carbohydrates | 3 | 2009 | 905 | 0.300 |
Why?
|
| Depressive Disorder | 4 | 2016 | 3747 | 0.290 |
Why?
|
| Sodium | 1 | 2012 | 1622 | 0.290 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2016 | 1953 | 0.290 |
Why?
|
| Genetic Loci | 2 | 2019 | 2575 | 0.290 |
Why?
|
| Insulin Resistance | 6 | 2008 | 3864 | 0.290 |
Why?
|
| Minerals | 4 | 1995 | 275 | 0.290 |
Why?
|
| Starvation | 2 | 2018 | 134 | 0.290 |
Why?
|
| Bromocriptine | 7 | 2010 | 111 | 0.280 |
Why?
|
| Dwarfism, Pituitary | 1 | 2006 | 46 | 0.280 |
Why?
|
| Neovascularization, Physiologic | 2 | 2012 | 1351 | 0.280 |
Why?
|
| Molecular Sequence Data | 16 | 2010 | 18111 | 0.280 |
Why?
|
| Nucleic Acid Conformation | 1 | 2009 | 913 | 0.270 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2006 | 61 | 0.270 |
Why?
|
| Outpatients | 3 | 2018 | 1487 | 0.270 |
Why?
|
| Gene Deletion | 2 | 2012 | 2751 | 0.270 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2006 | 88 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 23 | 2019 | 20130 | 0.260 |
Why?
|
| Activin Receptors, Type I | 3 | 2002 | 142 | 0.260 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2007 | 370 | 0.260 |
Why?
|
| Saliva | 3 | 2018 | 809 | 0.260 |
Why?
|
| Aged | 71 | 2020 | 163288 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 8432 | 0.260 |
Why?
|
| Puberty | 4 | 2011 | 490 | 0.260 |
Why?
|
| Psychotic Disorders | 3 | 2017 | 3046 | 0.250 |
Why?
|
| DNA, Complementary | 4 | 2010 | 2050 | 0.250 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2006 | 162 | 0.250 |
Why?
|
| Base Sequence | 14 | 2010 | 12797 | 0.250 |
Why?
|
| Contraceptives, Oral | 3 | 2009 | 564 | 0.250 |
Why?
|
| Tumor Cells, Cultured | 12 | 2006 | 6313 | 0.250 |
Why?
|
| Withholding Treatment | 1 | 2009 | 599 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 4751 | 0.250 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2003 | 424 | 0.250 |
Why?
|
| Sphenoid Sinus | 1 | 2005 | 99 | 0.250 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2010 | 857 | 0.250 |
Why?
|
| Genes, p53 | 1 | 2007 | 755 | 0.250 |
Why?
|
| Time Factors | 24 | 2020 | 40075 | 0.250 |
Why?
|
| Lipids | 8 | 2012 | 3307 | 0.250 |
Why?
|
| Response Elements | 1 | 2006 | 312 | 0.250 |
Why?
|
| Corticotropin-Releasing Hormone | 5 | 2012 | 369 | 0.250 |
Why?
|
| Premenopause | 5 | 2019 | 1033 | 0.240 |
Why?
|
| Dialysis | 1 | 2004 | 75 | 0.240 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2005 | 104 | 0.240 |
Why?
|
| Cerebral Cortex | 5 | 2015 | 5709 | 0.240 |
Why?
|
| Endocrinology | 4 | 2014 | 443 | 0.240 |
Why?
|
| Attitude to Health | 1 | 2013 | 2052 | 0.240 |
Why?
|
| Epigenesis, Genetic | 2 | 2015 | 3646 | 0.230 |
Why?
|
| Triiodothyronine | 6 | 2012 | 494 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 31 | 2021 | 35425 | 0.230 |
Why?
|
| Dietary Proteins | 1 | 2009 | 963 | 0.230 |
Why?
|
| Menstrual Cycle | 7 | 2006 | 551 | 0.230 |
Why?
|
| Appetite Regulation | 2 | 2019 | 88 | 0.230 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2005 | 331 | 0.230 |
Why?
|
| Polyuria | 2 | 2013 | 39 | 0.230 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2019 | 604 | 0.230 |
Why?
|
| Lipid Metabolism | 3 | 2018 | 1889 | 0.220 |
Why?
|
| Adiponectin | 6 | 2015 | 1101 | 0.220 |
Why?
|
| Stress, Psychological | 3 | 2015 | 4245 | 0.220 |
Why?
|
| Anthropometry | 6 | 2013 | 1350 | 0.220 |
Why?
|
| Sports | 4 | 2012 | 688 | 0.220 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 15535 | 0.220 |
Why?
|
| Azacitidine | 1 | 2005 | 347 | 0.220 |
Why?
|
| Calcium | 10 | 2014 | 5755 | 0.220 |
Why?
|
| Bradycardia | 1 | 2004 | 307 | 0.220 |
Why?
|
| Food Preferences | 2 | 2018 | 399 | 0.220 |
Why?
|
| Administration, Cutaneous | 4 | 2021 | 711 | 0.220 |
Why?
|
| Basal Metabolism | 2 | 2006 | 168 | 0.210 |
Why?
|
| Weight-Bearing | 4 | 2019 | 515 | 0.210 |
Why?
|
| Hypercalcemia | 1 | 2005 | 409 | 0.210 |
Why?
|
| Cyclic AMP | 1 | 2006 | 1472 | 0.210 |
Why?
|
| Brain | 8 | 2021 | 26388 | 0.210 |
Why?
|
| Extinction, Psychological | 3 | 2011 | 376 | 0.210 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 382 | 0.210 |
Why?
|
| Meningioma | 2 | 2010 | 1209 | 0.200 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 2690 | 0.200 |
Why?
|
| Hypoglycemia | 1 | 2009 | 861 | 0.200 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2013 | 548 | 0.200 |
Why?
|
| Homocystine | 1 | 2001 | 22 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 2943 | 0.200 |
Why?
|
| Abdomen | 2 | 2004 | 1118 | 0.200 |
Why?
|
| Appetite Stimulants | 2 | 2018 | 13 | 0.200 |
Why?
|
| Eating | 5 | 2019 | 1536 | 0.200 |
Why?
|
| Gonadal Hormones | 2 | 2011 | 29 | 0.190 |
Why?
|
| Affect | 5 | 2017 | 1475 | 0.190 |
Why?
|
| Risk Factors | 22 | 2020 | 72296 | 0.190 |
Why?
|
| Androstenedione | 1 | 2001 | 131 | 0.190 |
Why?
|
| Organ Size | 4 | 2014 | 2251 | 0.190 |
Why?
|
| Growth Substances | 2 | 2000 | 784 | 0.190 |
Why?
|
| Muscles | 4 | 2014 | 1614 | 0.190 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 3617 | 0.180 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2001 | 113 | 0.180 |
Why?
|
| Adolescent Behavior | 1 | 2009 | 1151 | 0.180 |
Why?
|
| Adaptation, Physiological | 2 | 2018 | 1312 | 0.180 |
Why?
|
| Immunohistochemistry | 10 | 2018 | 11366 | 0.180 |
Why?
|
| Peptide Fragments | 10 | 2011 | 5096 | 0.180 |
Why?
|
| Gonadotropins | 5 | 2017 | 241 | 0.180 |
Why?
|
| HIV Protease Inhibitors | 3 | 2000 | 430 | 0.180 |
Why?
|
| Analysis of Variance | 7 | 2010 | 6366 | 0.180 |
Why?
|
| C-Reactive Protein | 7 | 2010 | 3778 | 0.180 |
Why?
|
| Nutrition Surveys | 1 | 2006 | 1660 | 0.180 |
Why?
|
| Prevalence | 10 | 2019 | 15221 | 0.170 |
Why?
|
| Longitudinal Studies | 14 | 2021 | 13991 | 0.170 |
Why?
|
| Petrosal Sinus Sampling | 2 | 2012 | 23 | 0.170 |
Why?
|
| Adrenal Insufficiency | 5 | 2015 | 184 | 0.170 |
Why?
|
| Luteal Phase | 1 | 2019 | 147 | 0.170 |
Why?
|
| Puberty, Delayed | 3 | 1999 | 115 | 0.170 |
Why?
|
| Follicular Phase | 1 | 2019 | 153 | 0.170 |
Why?
|
| Receptors, Neuropeptide | 1 | 1999 | 111 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2009 | 4222 | 0.170 |
Why?
|
| Diphosphonates | 3 | 2011 | 623 | 0.170 |
Why?
|
| Placebos | 6 | 2008 | 1676 | 0.170 |
Why?
|
| Retrospective Studies | 27 | 2020 | 77460 | 0.160 |
Why?
|
| Prospective Studies | 20 | 2022 | 53290 | 0.160 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 871 | 0.160 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 475 | 0.160 |
Why?
|
| Dwarfism | 1 | 2019 | 146 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2021 | 381 | 0.160 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 1999 | 314 | 0.160 |
Why?
|
| Animals | 27 | 2019 | 168768 | 0.160 |
Why?
|
| Osteocalcin | 4 | 2002 | 273 | 0.160 |
Why?
|
| Galactorrhea | 2 | 1997 | 24 | 0.160 |
Why?
|
| Athletes | 4 | 2019 | 1093 | 0.160 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 19 | 0.160 |
Why?
|
| Hyperphagia | 1 | 2018 | 136 | 0.160 |
Why?
|
| Triglycerides | 5 | 2008 | 2453 | 0.150 |
Why?
|
| Health | 2 | 2012 | 394 | 0.150 |
Why?
|
| Heart Ventricles | 1 | 2010 | 3817 | 0.150 |
Why?
|
| Alternative Splicing | 3 | 2002 | 1117 | 0.150 |
Why?
|
| Aging | 7 | 2017 | 8664 | 0.150 |
Why?
|
| Homocysteine | 1 | 2001 | 647 | 0.150 |
Why?
|
| Treatment Outcome | 19 | 2021 | 63107 | 0.150 |
Why?
|
| Single-Blind Method | 5 | 2012 | 1590 | 0.150 |
Why?
|
| Exercise | 9 | 2013 | 5615 | 0.150 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2017 | 14 | 0.150 |
Why?
|
| Satiation | 2 | 2019 | 80 | 0.150 |
Why?
|
| Quality of Life | 10 | 2016 | 12802 | 0.150 |
Why?
|
| Antipsychotic Agents | 3 | 2012 | 3057 | 0.150 |
Why?
|
| Menstruation Disturbances | 2 | 2017 | 148 | 0.150 |
Why?
|
| Endocrine Glands | 1 | 1997 | 103 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 16690 | 0.150 |
Why?
|
| Hippocampus | 4 | 2017 | 3675 | 0.150 |
Why?
|
| Pelvic Bones | 1 | 2019 | 265 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2000 | 2232 | 0.140 |
Why?
|
| Growth | 2 | 2009 | 376 | 0.140 |
Why?
|
| Fear | 3 | 2011 | 1440 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2019 | 10483 | 0.140 |
Why?
|
| Body Fat Distribution | 2 | 2009 | 244 | 0.140 |
Why?
|
| Glucose Tolerance Test | 3 | 2017 | 1151 | 0.140 |
Why?
|
| Circadian Rhythm | 8 | 2018 | 2624 | 0.140 |
Why?
|
| Area Under Curve | 3 | 2009 | 1655 | 0.140 |
Why?
|
| Subcutaneous Fat | 2 | 2017 | 391 | 0.140 |
Why?
|
| Muscle, Skeletal | 9 | 2019 | 4925 | 0.140 |
Why?
|
| Caloric Restriction | 2 | 2018 | 302 | 0.130 |
Why?
|
| Gastric Emptying | 1 | 2018 | 233 | 0.130 |
Why?
|
| Monte Carlo Method | 1 | 2021 | 1254 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 6036 | 0.130 |
Why?
|
| Pulsatile Flow | 3 | 2005 | 332 | 0.130 |
Why?
|
| Interleukin-6 | 5 | 2009 | 3203 | 0.130 |
Why?
|
| Mutation | 7 | 2013 | 29786 | 0.130 |
Why?
|
| Vitamin D | 6 | 2019 | 3224 | 0.130 |
Why?
|
| Aged, 80 and over | 16 | 2019 | 57776 | 0.130 |
Why?
|
| Thyroid Gland | 3 | 2013 | 1173 | 0.130 |
Why?
|
| Activin Receptors | 3 | 2000 | 43 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2000 | 632 | 0.130 |
Why?
|
| Dexamethasone | 5 | 2009 | 1951 | 0.130 |
Why?
|
| Affective Symptoms | 1 | 2017 | 407 | 0.120 |
Why?
|
| Nutrition Assessment | 3 | 2004 | 723 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.120 |
Why?
|
| Verbal Learning | 1 | 2017 | 468 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2004 | 2865 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2007 | 1730 | 0.120 |
Why?
|
| Delayed-Action Preparations | 3 | 2016 | 968 | 0.120 |
Why?
|
| Gonads | 2 | 2009 | 109 | 0.120 |
Why?
|
| Sella Turcica | 2 | 2010 | 119 | 0.120 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 977 | 0.120 |
Why?
|
| Point Mutation | 2 | 2004 | 1624 | 0.120 |
Why?
|
| Thyrotropin-Releasing Hormone | 8 | 1998 | 147 | 0.120 |
Why?
|
| Thyroid Hormones | 2 | 2011 | 390 | 0.120 |
Why?
|
| Trans-Activators | 1 | 2004 | 2926 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 415 | 0.120 |
Why?
|
| Somatomedins | 3 | 2009 | 192 | 0.120 |
Why?
|
| Peptides | 4 | 2013 | 4410 | 0.120 |
Why?
|
| Receptors, LHRH | 1 | 1994 | 160 | 0.120 |
Why?
|
| Radiosurgery | 3 | 2008 | 1329 | 0.120 |
Why?
|
| Neuropeptides | 1 | 1999 | 942 | 0.120 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2013 | 19 | 0.120 |
Why?
|
| Genes, ras | 2 | 1994 | 690 | 0.120 |
Why?
|
| Nocturnal Enuresis | 1 | 2013 | 12 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9445 | 0.120 |
Why?
|
| Cholesterol | 4 | 2008 | 2919 | 0.120 |
Why?
|
| Sequence Deletion | 3 | 2019 | 1525 | 0.120 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 13693 | 0.120 |
Why?
|
| Prognosis | 9 | 2020 | 29060 | 0.110 |
Why?
|
| Mice | 10 | 2019 | 81201 | 0.110 |
Why?
|
| Pregnancy Complications | 2 | 2006 | 2861 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2000 | 904 | 0.110 |
Why?
|
| Diastole | 1 | 2015 | 791 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 1856 | 0.110 |
Why?
|
| Binge-Eating Disorder | 1 | 2015 | 137 | 0.110 |
Why?
|
| Mice, Knockout | 6 | 2019 | 14561 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 365 | 0.110 |
Why?
|
| Thorax | 2 | 2008 | 547 | 0.110 |
Why?
|
| Chemical Phenomena | 1 | 2013 | 518 | 0.110 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2013 | 117 | 0.110 |
Why?
|
| Hospitals, General | 1 | 1997 | 749 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2019 | 10943 | 0.110 |
Why?
|
| Calorimetry, Indirect | 2 | 2006 | 183 | 0.110 |
Why?
|
| Hip Fractures | 2 | 2014 | 955 | 0.110 |
Why?
|
| Diaphyses | 1 | 2012 | 65 | 0.110 |
Why?
|
| Menarche | 3 | 2004 | 516 | 0.110 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 401 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 6489 | 0.110 |
Why?
|
| Acetylation | 1 | 2015 | 1084 | 0.110 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2013 | 113 | 0.110 |
Why?
|
| Brain Injuries | 2 | 2015 | 2029 | 0.100 |
Why?
|
| Mental Disorders | 3 | 2017 | 6598 | 0.100 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 39052 | 0.100 |
Why?
|
| Porosity | 1 | 2013 | 362 | 0.100 |
Why?
|
| Water-Electrolyte Balance | 1 | 2013 | 346 | 0.100 |
Why?
|
| Visual Perception | 1 | 2021 | 1420 | 0.100 |
Why?
|
| Carbohydrate Metabolism | 2 | 2018 | 265 | 0.100 |
Why?
|
| Weight Lifting | 2 | 2004 | 131 | 0.100 |
Why?
|
| Brain Mapping | 4 | 2018 | 6670 | 0.100 |
Why?
|
| Administration, Oral | 3 | 2018 | 3914 | 0.100 |
Why?
|
| Prader-Willi Syndrome | 1 | 2012 | 79 | 0.100 |
Why?
|
| Metabolome | 1 | 2018 | 895 | 0.100 |
Why?
|
| Thermogenesis | 1 | 2015 | 434 | 0.100 |
Why?
|
| Cognition | 4 | 2019 | 6770 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2916 | 0.100 |
Why?
|
| RNA, Neoplasm | 3 | 1992 | 769 | 0.100 |
Why?
|
| Nelson Syndrome | 2 | 2008 | 20 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2019 | 2618 | 0.100 |
Why?
|
| Cholesterol, HDL | 4 | 2001 | 1813 | 0.100 |
Why?
|
| Cell Line | 4 | 2009 | 16000 | 0.100 |
Why?
|
| Risk | 2 | 2014 | 9688 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 1997 | 934 | 0.090 |
Why?
|
| Massachusetts | 5 | 2012 | 8662 | 0.090 |
Why?
|
| Conditioning, Classical | 2 | 2011 | 366 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 2765 | 0.090 |
Why?
|
| Extremities | 2 | 2008 | 866 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2003 | 2304 | 0.090 |
Why?
|
| Visual Fields | 3 | 2010 | 1047 | 0.090 |
Why?
|
| Dopamine | 6 | 1991 | 1591 | 0.090 |
Why?
|
| COS Cells | 2 | 2004 | 1161 | 0.090 |
Why?
|
| Arachnoid | 1 | 2010 | 48 | 0.090 |
Why?
|
| Adrenal Glands | 1 | 2013 | 546 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2013 | 566 | 0.090 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2000 | 2560 | 0.090 |
Why?
|
| Sex Factors | 5 | 2017 | 10400 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 8 | 1997 | 6171 | 0.090 |
Why?
|
| Aftercare | 1 | 2016 | 870 | 0.090 |
Why?
|
| Potassium | 2 | 2004 | 1336 | 0.090 |
Why?
|
| Placentation | 1 | 2010 | 82 | 0.090 |
Why?
|
| Thyroxine | 4 | 2012 | 667 | 0.090 |
Why?
|
| Memory | 1 | 2019 | 2174 | 0.090 |
Why?
|
| GTP-Binding Proteins | 2 | 1992 | 970 | 0.090 |
Why?
|
| Positron-Emission Tomography | 4 | 2013 | 6234 | 0.090 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 1783 | 0.090 |
Why?
|
| Hyponatremia | 1 | 2012 | 298 | 0.090 |
Why?
|
| Osteoblasts | 1 | 1995 | 1166 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2014 | 8319 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 5692 | 0.090 |
Why?
|
| Gallbladder | 2 | 2009 | 302 | 0.090 |
Why?
|
| Parathyroid Hormone | 5 | 1996 | 1800 | 0.090 |
Why?
|
| Hematopoiesis | 1 | 2019 | 2073 | 0.090 |
Why?
|
| Adipokines | 1 | 2011 | 320 | 0.090 |
Why?
|
| Satiety Response | 1 | 2009 | 49 | 0.090 |
Why?
|
| Statistics as Topic | 3 | 2012 | 2373 | 0.090 |
Why?
|
| Luciferases | 2 | 2002 | 733 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2013 | 627 | 0.090 |
Why?
|
| Energy Metabolism | 4 | 2014 | 2897 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 399 | 0.080 |
Why?
|
| Transfection | 3 | 2002 | 5895 | 0.080 |
Why?
|
| Medical Informatics | 1 | 2016 | 745 | 0.080 |
Why?
|
| Neurology | 1 | 1997 | 763 | 0.080 |
Why?
|
| Professional Practice | 1 | 2011 | 326 | 0.080 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 108 | 0.080 |
Why?
|
| New England | 1 | 2012 | 1022 | 0.080 |
Why?
|
| Age Factors | 8 | 2020 | 18373 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 7282 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2015 | 696 | 0.080 |
Why?
|
| Fathers | 1 | 2011 | 358 | 0.080 |
Why?
|
| Mice, Nude | 1 | 2015 | 3689 | 0.080 |
Why?
|
| Pregnancy | 7 | 2019 | 29144 | 0.080 |
Why?
|
| Fats | 1 | 2009 | 102 | 0.080 |
Why?
|
| Nose | 1 | 2012 | 509 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2021 | 8949 | 0.080 |
Why?
|
| Mortality | 1 | 2020 | 2864 | 0.080 |
Why?
|
| Adipocytes | 1 | 2015 | 1185 | 0.080 |
Why?
|
| Cluster Analysis | 3 | 2005 | 2715 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 712 | 0.080 |
Why?
|
| Trabecular Meshwork | 1 | 2008 | 99 | 0.080 |
Why?
|
| Calcium, Dietary | 2 | 2019 | 526 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2008 | 123 | 0.080 |
Why?
|
| Drug Combinations | 2 | 2004 | 1958 | 0.080 |
Why?
|
| Drug Administration Schedule | 4 | 2019 | 4933 | 0.080 |
Why?
|
| Hypertension | 2 | 2013 | 8479 | 0.080 |
Why?
|
| Disease Management | 1 | 2018 | 2460 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3480 | 0.080 |
Why?
|
| Transcription Factor Pit-1 | 1 | 2007 | 16 | 0.080 |
Why?
|
| Brain Neoplasms | 3 | 2013 | 8861 | 0.080 |
Why?
|
| HIV Infections | 5 | 2004 | 16715 | 0.080 |
Why?
|
| Carrier Proteins | 3 | 1996 | 5023 | 0.080 |
Why?
|
| Exons | 3 | 2019 | 2439 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2019 | 23404 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 547 | 0.070 |
Why?
|
| Lipoproteins | 2 | 2012 | 878 | 0.070 |
Why?
|
| Trace Elements | 2 | 2006 | 198 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 4 | 2005 | 1799 | 0.070 |
Why?
|
| Nerve Net | 2 | 2016 | 2175 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2004 | 8436 | 0.070 |
Why?
|
| Echocardiography | 2 | 2010 | 5099 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 3873 | 0.070 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2012 | 838 | 0.070 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 322 | 0.070 |
Why?
|
| Comorbidity | 3 | 2015 | 10388 | 0.070 |
Why?
|
| Metformin | 2 | 2004 | 836 | 0.070 |
Why?
|
| Autonomic Nervous System | 1 | 2012 | 672 | 0.070 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 2008 | 213 | 0.070 |
Why?
|
| Remission Induction | 4 | 2015 | 2385 | 0.070 |
Why?
|
| Follistatin | 2 | 2000 | 141 | 0.070 |
Why?
|
| Sphenoid Bone | 2 | 2008 | 172 | 0.070 |
Why?
|
| Self Report | 2 | 2016 | 3553 | 0.070 |
Why?
|
| Motivation | 2 | 2013 | 1971 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 9647 | 0.070 |
Why?
|
| Placenta | 2 | 2019 | 1699 | 0.070 |
Why?
|
| Psychometrics | 2 | 2014 | 3003 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 9240 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2887 | 0.070 |
Why?
|
| Growth Plate | 1 | 2008 | 274 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2019 | 3390 | 0.070 |
Why?
|
| Anti-HIV Agents | 2 | 2000 | 4255 | 0.070 |
Why?
|
| Neurotic Disorders | 1 | 2006 | 79 | 0.070 |
Why?
|
| Weight Loss | 4 | 2000 | 2625 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2012 | 1183 | 0.070 |
Why?
|
| Physicians, Family | 1 | 2008 | 345 | 0.070 |
Why?
|
| Combined Modality Therapy | 5 | 2008 | 8642 | 0.070 |
Why?
|
| Seasons | 1 | 2012 | 1493 | 0.070 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 188 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2013 | 3001 | 0.070 |
Why?
|
| Body Image | 1 | 2010 | 610 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 183 | 0.070 |
Why?
|
| Transcription Initiation Site | 1 | 2006 | 196 | 0.070 |
Why?
|
| Vitamins | 2 | 2006 | 1623 | 0.070 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2013 | 711 | 0.070 |
Why?
|
| Multivariate Analysis | 5 | 2012 | 12244 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2010 | 1252 | 0.060 |
Why?
|
| Food Deprivation | 1 | 2005 | 116 | 0.060 |
Why?
|
| Blood Chemical Analysis | 2 | 2005 | 440 | 0.060 |
Why?
|
| Apolipoproteins B | 1 | 2006 | 374 | 0.060 |
Why?
|
| Diet Records | 1 | 2006 | 425 | 0.060 |
Why?
|
| Amyloid | 1 | 2009 | 795 | 0.060 |
Why?
|
| Arousal | 2 | 2012 | 1164 | 0.060 |
Why?
|
| ROC Curve | 3 | 2020 | 3528 | 0.060 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2008 | 450 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 973 | 0.060 |
Why?
|
| Neuroendocrine Tumors | 1 | 2010 | 594 | 0.060 |
Why?
|
| Phosphorus | 2 | 1995 | 338 | 0.060 |
Why?
|
| Age Determination by Skeleton | 1 | 2004 | 129 | 0.060 |
Why?
|
| Inflammation | 3 | 2001 | 10637 | 0.060 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 894 | 0.060 |
Why?
|
| Injections, Subcutaneous | 3 | 1995 | 667 | 0.060 |
Why?
|
| Hematocrit | 1 | 2005 | 636 | 0.060 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 1995 | 216 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2008 | 2327 | 0.060 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 14723 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 3130 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2007 | 640 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2004 | 156 | 0.060 |
Why?
|
| Open Reading Frames | 1 | 2007 | 811 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2006 | 732 | 0.060 |
Why?
|
| Hematologic Tests | 1 | 2004 | 240 | 0.060 |
Why?
|
| Protein Folding | 1 | 2007 | 840 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2006 | 514 | 0.060 |
Why?
|
| Mice, Inbred C3H | 2 | 2015 | 964 | 0.060 |
Why?
|
| Periodicity | 1 | 2005 | 364 | 0.060 |
Why?
|
| Blotting, Southern | 3 | 1997 | 803 | 0.060 |
Why?
|
| Diagnosis, Differential | 5 | 2010 | 12961 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2009 | 1915 | 0.060 |
Why?
|
| Kinetics | 7 | 2001 | 6476 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 21833 | 0.060 |
Why?
|
| Gyrus Cinguli | 2 | 2010 | 1091 | 0.060 |
Why?
|
| Mink | 1 | 2002 | 44 | 0.060 |
Why?
|
| Algorithms | 3 | 2021 | 13882 | 0.060 |
Why?
|
| Activin Receptors, Type II | 2 | 2000 | 127 | 0.060 |
Why?
|
| Family Characteristics | 1 | 2008 | 1000 | 0.060 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2004 | 138 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1983 | 177 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2007 | 638 | 0.050 |
Why?
|
| Osteoprotegerin | 1 | 2003 | 176 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2006 | 1030 | 0.050 |
Why?
|
| Receptors, Leptin | 1 | 2004 | 361 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 15078 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1423 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 1637 | 0.050 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2013 | 1632 | 0.050 |
Why?
|
| Solubility | 1 | 2004 | 1088 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2006 | 760 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2005 | 684 | 0.050 |
Why?
|
| Inflammation Mediators | 2 | 2012 | 1888 | 0.050 |
Why?
|
| Fluoxetine | 1 | 2006 | 749 | 0.050 |
Why?
|
| Pirenzepine | 1 | 2002 | 115 | 0.050 |
Why?
|
| Blotting, Western | 2 | 2000 | 5181 | 0.050 |
Why?
|
| Software | 1 | 2016 | 4441 | 0.050 |
Why?
|
| Carcinoma | 1 | 1994 | 2375 | 0.050 |
Why?
|
| Tryptophan | 1 | 2004 | 478 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 1284 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2010 | 1074 | 0.050 |
Why?
|
| Alanine | 1 | 2004 | 572 | 0.050 |
Why?
|
| Hypoglycemic Agents | 2 | 2004 | 2873 | 0.050 |
Why?
|
| Acylation | 2 | 2014 | 107 | 0.050 |
Why?
|
| Nafarelin | 2 | 1998 | 27 | 0.050 |
Why?
|
| Disease Progression | 1 | 2018 | 13286 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 937 | 0.050 |
Why?
|
| Lithium | 1 | 2004 | 601 | 0.050 |
Why?
|
| Fetus | 1 | 2009 | 1880 | 0.050 |
Why?
|
| Space Perception | 1 | 2004 | 475 | 0.050 |
Why?
|
| Microscopy, Electron | 2 | 2000 | 2646 | 0.050 |
Why?
|
| Radionuclide Imaging | 5 | 1989 | 2031 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 3921 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6539 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 2716 | 0.050 |
Why?
|
| Self Concept | 1 | 2007 | 1025 | 0.050 |
Why?
|
| Genes, jun | 1 | 2000 | 71 | 0.050 |
Why?
|
| Leg | 2 | 2010 | 1116 | 0.050 |
Why?
|
| Amino Acid Sequence | 4 | 2004 | 13814 | 0.050 |
Why?
|
| Neuropsychological Tests | 3 | 2019 | 6994 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 595 | 0.050 |
Why?
|
| Mothers | 1 | 2011 | 2165 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 12356 | 0.050 |
Why?
|
| Klinefelter Syndrome | 1 | 2000 | 48 | 0.050 |
Why?
|
| Radiography | 1 | 2012 | 7023 | 0.050 |
Why?
|
| CpG Islands | 1 | 2005 | 1170 | 0.050 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1992 | 769 | 0.050 |
Why?
|
| Social Behavior | 1 | 2007 | 1127 | 0.050 |
Why?
|
| Mental Recall | 2 | 2017 | 1206 | 0.050 |
Why?
|
| Femur Neck | 2 | 2019 | 309 | 0.050 |
Why?
|
| Serum Amyloid A Protein | 1 | 2000 | 121 | 0.050 |
Why?
|
| Viral Load | 2 | 2000 | 3300 | 0.050 |
Why?
|
| Amino Acids | 1 | 2006 | 1737 | 0.050 |
Why?
|
| Prolactin-Releasing Hormone | 1 | 1999 | 3 | 0.050 |
Why?
|
| Genomics | 1 | 2016 | 5717 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 2019 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 1851 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 2838 | 0.050 |
Why?
|
| Thymidine | 1 | 2000 | 310 | 0.040 |
Why?
|
| Risperidone | 1 | 2002 | 383 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2000 | 286 | 0.040 |
Why?
|
| Boston | 1 | 2013 | 9312 | 0.040 |
Why?
|
| Psychopathology | 1 | 2023 | 409 | 0.040 |
Why?
|
| Reward | 2 | 2018 | 940 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 9274 | 0.040 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 1425 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 1524 | 0.040 |
Why?
|
| Turner Syndrome | 1 | 2000 | 130 | 0.040 |
Why?
|
| Rats | 6 | 2011 | 24252 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 4042 | 0.040 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 7721 | 0.040 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 854 | 0.040 |
Why?
|
| Medical Staff, Hospital | 1 | 2003 | 601 | 0.040 |
Why?
|
| Macromolecular Substances | 2 | 2000 | 1454 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2000 | 552 | 0.040 |
Why?
|
| Alleles | 1 | 2010 | 6933 | 0.040 |
Why?
|
| K562 Cells | 1 | 2000 | 635 | 0.040 |
Why?
|
| Desogestrel | 1 | 2018 | 23 | 0.040 |
Why?
|
| Clozapine | 1 | 2002 | 498 | 0.040 |
Why?
|
| Models, Biological | 1 | 2015 | 9584 | 0.040 |
Why?
|
| Phosphates | 1 | 2002 | 785 | 0.040 |
Why?
|
| 17-Hydroxycorticosteroids | 1 | 1998 | 40 | 0.040 |
Why?
|
| Imidazoles | 1 | 2005 | 1206 | 0.040 |
Why?
|
| Transdermal Patch | 1 | 2018 | 51 | 0.040 |
Why?
|
| Fatty Acids | 2 | 2015 | 1809 | 0.040 |
Why?
|
| Protease Inhibitors | 2 | 2001 | 791 | 0.040 |
Why?
|
| Psychophysics | 2 | 2011 | 309 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 4851 | 0.040 |
Why?
|
| Heart Rate | 2 | 2012 | 4092 | 0.040 |
Why?
|
| Steroids | 2 | 2017 | 930 | 0.040 |
Why?
|
| Mice, Inbred DBA | 1 | 2019 | 642 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2015 | 1842 | 0.040 |
Why?
|
| Diagnostic Errors | 2 | 2004 | 1257 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 5321 | 0.040 |
Why?
|
| Alkaline Phosphatase | 2 | 1999 | 867 | 0.040 |
Why?
|
| Research | 2 | 2016 | 1999 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 2001 | 527 | 0.040 |
Why?
|
| Clone Cells | 2 | 1992 | 1692 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 4320 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 603 | 0.040 |
Why?
|
| Iodide Peroxidase | 1 | 2019 | 293 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2001 | 548 | 0.040 |
Why?
|
| Cholesterol, LDL | 2 | 2001 | 2355 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2010 | 5006 | 0.040 |
Why?
|
| Arm | 1 | 2000 | 589 | 0.040 |
Why?
|
| Hypothyroidism | 4 | 2015 | 658 | 0.040 |
Why?
|
| Sports Medicine | 1 | 1980 | 225 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2003 | 3130 | 0.040 |
Why?
|
| Megestrol Acetate | 1 | 1996 | 18 | 0.040 |
Why?
|
| E-Selectin | 2 | 2010 | 579 | 0.040 |
Why?
|
| Skull Base Neoplasms | 1 | 2001 | 284 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 7914 | 0.040 |
Why?
|
| Consensus | 2 | 2018 | 2960 | 0.040 |
Why?
|
| Diabetes, Gestational | 1 | 2006 | 1184 | 0.040 |
Why?
|
| Photic Stimulation | 2 | 2014 | 2026 | 0.040 |
Why?
|
| Mass Screening | 1 | 2012 | 5253 | 0.040 |
Why?
|
| Chromosomes | 1 | 2000 | 596 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2006 | 2050 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2000 | 415 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2000 | 1547 | 0.040 |
Why?
|
| Genetic Markers | 2 | 2012 | 2634 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2009 | 5984 | 0.040 |
Why?
|
| Lipoprotein(a) | 1 | 2000 | 435 | 0.030 |
Why?
|
| Brain Hemorrhage, Traumatic | 1 | 2015 | 18 | 0.030 |
Why?
|
| Sexual Behavior | 1 | 2006 | 2055 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2020 | 1588 | 0.030 |
Why?
|
| Molecular Probes | 2 | 1995 | 316 | 0.030 |
Why?
|
| Motor Activity | 1 | 2006 | 2715 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 1998 | 644 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2013 | 11486 | 0.030 |
Why?
|
| Melanoma | 1 | 2014 | 5511 | 0.030 |
Why?
|
| Cues | 1 | 2021 | 875 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2006 | 4162 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2011 | 3751 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1342 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2018 | 546 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 1995 | 185 | 0.030 |
Why?
|
| Running | 1 | 1980 | 480 | 0.030 |
Why?
|
| Recurrence | 4 | 2015 | 8340 | 0.030 |
Why?
|
| Arginine | 1 | 1998 | 944 | 0.030 |
Why?
|
| Follicle Stimulating Hormone, beta Subunit | 2 | 1992 | 58 | 0.030 |
Why?
|
| Reproduction | 1 | 2019 | 668 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2004 | 1916 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 4805 | 0.030 |
Why?
|
| Schizophrenia | 2 | 2004 | 6882 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2017 | 651 | 0.030 |
Why?
|
| Electric Impedance | 1 | 1998 | 729 | 0.030 |
Why?
|
| Metoclopramide | 2 | 1991 | 51 | 0.030 |
Why?
|
| Embryonic Development | 1 | 2019 | 711 | 0.030 |
Why?
|
| Folic Acid | 1 | 2001 | 1300 | 0.030 |
Why?
|
| Densitometry | 2 | 1986 | 156 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2004 | 2926 | 0.030 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2013 | 43 | 0.030 |
Why?
|
| Collagen | 1 | 2002 | 2688 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2021 | 2700 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 740 | 0.030 |
Why?
|
| Logistic Models | 2 | 2020 | 13409 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1994 | 427 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 2029 | 0.030 |
Why?
|
| Salivary Glands | 1 | 1995 | 229 | 0.030 |
Why?
|
| Genes, Retinoblastoma | 1 | 1993 | 136 | 0.030 |
Why?
|
| Patient Selection | 2 | 2019 | 4216 | 0.030 |
Why?
|
| Heart | 1 | 2006 | 4464 | 0.030 |
Why?
|
| Age of Onset | 1 | 2000 | 3270 | 0.030 |
Why?
|
| Adenoma, Chromophobe | 2 | 1983 | 16 | 0.030 |
Why?
|
| Choristoma | 1 | 1995 | 214 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 941 | 0.030 |
Why?
|
| Microbial Collagenase | 1 | 1973 | 122 | 0.030 |
Why?
|
| Endometriosis | 2 | 1998 | 839 | 0.030 |
Why?
|
| Oxygen | 2 | 2017 | 4189 | 0.030 |
Why?
|
| Ricin | 1 | 1992 | 72 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 2274 | 0.030 |
Why?
|
| Chondrosarcoma | 2 | 2001 | 309 | 0.030 |
Why?
|
| Depression, Chemical | 1 | 1992 | 191 | 0.030 |
Why?
|
| Plant Lectins | 1 | 1992 | 104 | 0.030 |
Why?
|
| Histocytochemistry | 3 | 1988 | 719 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 8300 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1991 | 2186 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 780 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2004 | 8551 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2019 | 23336 | 0.030 |
Why?
|
| Chordoma | 2 | 2001 | 359 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3773 | 0.030 |
Why?
|
| Pressure Ulcer | 1 | 1973 | 155 | 0.030 |
Why?
|
| Frontal Lobe | 2 | 2010 | 1406 | 0.030 |
Why?
|
| Osteoclasts | 1 | 1995 | 729 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2013 | 140 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2012 | 187 | 0.020 |
Why?
|
| Physical Endurance | 2 | 2004 | 370 | 0.020 |
Why?
|
| Workflow | 1 | 2016 | 847 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2014 | 351 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 1992 | 683 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1992 | 549 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 428 | 0.020 |
Why?
|
| Propionates | 1 | 2011 | 169 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2006 | 4253 | 0.020 |
Why?
|
| Calcitriol | 2 | 1989 | 297 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 1990 | 68 | 0.020 |
Why?
|
| Phosphoglycerate Kinase | 1 | 1990 | 68 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 405 | 0.020 |
Why?
|
| Exercise Test | 1 | 1998 | 2073 | 0.020 |
Why?
|
| New Zealand | 1 | 2011 | 355 | 0.020 |
Why?
|
| Debridement | 1 | 1973 | 492 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 670 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1992 | 1581 | 0.020 |
Why?
|
| Central Nervous System Cysts | 1 | 2010 | 58 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 1992 | 414 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1990 | 110 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 6386 | 0.020 |
Why?
|
| Wnt Proteins | 1 | 2014 | 721 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2009 | 19905 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 336 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 1990 | 109 | 0.020 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2009 | 41 | 0.020 |
Why?
|
| Lectins | 1 | 1992 | 513 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 819 | 0.020 |
Why?
|
| Metabolomics | 1 | 2018 | 1485 | 0.020 |
Why?
|
| Kidney | 2 | 1995 | 7184 | 0.020 |
Why?
|
| Cause of Death | 1 | 2020 | 3582 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 1343 | 0.020 |
Why?
|
| Cells, Cultured | 6 | 1995 | 19233 | 0.020 |
Why?
|
| Patient Preference | 1 | 2016 | 889 | 0.020 |
Why?
|
| Dopamine Agents | 1 | 1990 | 189 | 0.020 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1990 | 211 | 0.020 |
Why?
|
| X Chromosome | 1 | 1992 | 814 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1997 | 2190 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1990 | 375 | 0.020 |
Why?
|
| Metyrapone | 1 | 2008 | 23 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2011 | 575 | 0.020 |
Why?
|
| Mitotane | 1 | 2008 | 18 | 0.020 |
Why?
|
| Glioma | 1 | 2003 | 3401 | 0.020 |
Why?
|
| Astrocytoma | 1 | 2013 | 790 | 0.020 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2008 | 30 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2010 | 402 | 0.020 |
Why?
|
| DNA | 1 | 2002 | 7294 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2015 | 12207 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2001 | 3296 | 0.020 |
Why?
|
| Gaucher Disease | 1 | 1989 | 112 | 0.020 |
Why?
|
| Hypophysectomy | 1 | 2008 | 113 | 0.020 |
Why?
|
| Sexual Development | 1 | 2008 | 34 | 0.020 |
Why?
|
| Executive Function | 1 | 2017 | 1364 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 4 | 1992 | 1375 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1988 | 228 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 1996 | 2007 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 1167 | 0.020 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 281 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 2009 | 252 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 2014 | 1221 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1998 | 2684 | 0.020 |
Why?
|
| Skull Neoplasms | 1 | 1988 | 173 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2013 | 2297 | 0.020 |
Why?
|
| Ependymoma | 1 | 2010 | 334 | 0.020 |
Why?
|
| Phenols | 1 | 2011 | 497 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1989 | 476 | 0.020 |
Why?
|
| Learning | 1 | 2017 | 1711 | 0.020 |
Why?
|
| Methylation | 1 | 1990 | 1106 | 0.020 |
Why?
|
| Bipolar Disorder | 1 | 2004 | 5027 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2000 | 3854 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 9955 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 357 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 1270 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9735 | 0.020 |
Why?
|
| Neoplasms | 2 | 2014 | 21696 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1997 | 1622 | 0.020 |
Why?
|
| United States | 4 | 2019 | 69872 | 0.020 |
Why?
|
| Nitriles | 1 | 2011 | 955 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 1903 | 0.020 |
Why?
|
| Hydroxyestrones | 1 | 1985 | 17 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2008 | 341 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2019 | 6194 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 1998 | 3395 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 2065 | 0.020 |
Why?
|
| Morbidity | 2 | 2003 | 1768 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 3616 | 0.020 |
Why?
|
| Bulimia | 1 | 1988 | 383 | 0.020 |
Why?
|
| Internationality | 1 | 2011 | 1002 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 3743 | 0.020 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2013 | 944 | 0.020 |
Why?
|
| China | 1 | 2011 | 2245 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2009 | 1159 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 2002 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 1997 | 2291 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 1460 | 0.020 |
Why?
|
| Galvanic Skin Response | 1 | 2006 | 349 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2004 | 80 | 0.020 |
Why?
|
| Neurosurgery | 1 | 2011 | 643 | 0.020 |
Why?
|
| Seizures | 2 | 2015 | 2859 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 592 | 0.020 |
Why?
|
| Estrone | 1 | 1985 | 240 | 0.020 |
Why?
|
| Osteolysis | 1 | 1986 | 270 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 3338 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1990 | 1276 | 0.020 |
Why?
|
| Ovary | 1 | 2009 | 981 | 0.020 |
Why?
|
| Dominance, Cerebral | 1 | 2006 | 635 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 1990 | 971 | 0.010 |
Why?
|
| Ketones | 1 | 1985 | 188 | 0.010 |
Why?
|
| Occipital Lobe | 1 | 2006 | 379 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 3595 | 0.010 |
Why?
|
| Forearm | 1 | 1986 | 409 | 0.010 |
Why?
|
| Databases, Factual | 2 | 2014 | 7730 | 0.010 |
Why?
|
| Subcutaneous Tissue | 1 | 2004 | 135 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2019 | 25628 | 0.010 |
Why?
|
| Water | 1 | 2010 | 1395 | 0.010 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1983 | 174 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2016 | 3531 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 2004 | 588 | 0.010 |
Why?
|
| Cattle | 3 | 1983 | 3922 | 0.010 |
Why?
|
| Thigh | 1 | 2004 | 247 | 0.010 |
Why?
|
| Dementia | 1 | 2017 | 2518 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2005 | 479 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1983 | 668 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1990 | 1403 | 0.010 |
Why?
|
| Protons | 1 | 2007 | 1127 | 0.010 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2004 | 288 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3339 | 0.010 |
Why?
|
| Infant | 2 | 2019 | 35134 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1997 | 6542 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 2917 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2006 | 1767 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2012 | 2974 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2019 | 41005 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2011 | 1972 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2020 | 40559 | 0.010 |
Why?
|
| Biopsy | 1 | 1992 | 6755 | 0.010 |
Why?
|
| Prednisone | 1 | 2005 | 1574 | 0.010 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1980 | 41 | 0.010 |
Why?
|
| Homeostasis | 1 | 1991 | 3339 | 0.010 |
Why?
|
| Wasting Syndrome | 1 | 2000 | 101 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7785 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 2001 | 2879 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2001 | 876 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 335 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 2000 | 286 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1999 | 288 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 1993 | 5856 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2006 | 1670 | 0.010 |
Why?
|
| Reoperation | 1 | 2008 | 4201 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1983 | 1240 | 0.010 |
Why?
|
| Ovulation | 1 | 1998 | 189 | 0.010 |
Why?
|
| DNA, Neoplasm | 2 | 1993 | 1758 | 0.010 |
Why?
|
| Postoperative Complications | 3 | 2008 | 15297 | 0.010 |
Why?
|
| Naloxone | 1 | 1980 | 367 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 615 | 0.010 |
Why?
|
| Emotions | 1 | 2009 | 2659 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 2016 | 0.010 |
Why?
|
| Hospital Costs | 1 | 2003 | 985 | 0.010 |
Why?
|
| Physical Fitness | 1 | 2001 | 732 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2002 | 1101 | 0.010 |
Why?
|
| Urinalysis | 1 | 1998 | 369 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 20824 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 8038 | 0.010 |
Why?
|
| Survival Rate | 2 | 2001 | 12788 | 0.010 |
Why?
|
| Pituitary Function Tests | 2 | 1985 | 27 | 0.010 |
Why?
|
| Biliary Tract | 1 | 1995 | 134 | 0.010 |
Why?
|
| Iodine Radioisotopes | 2 | 1989 | 1032 | 0.010 |
Why?
|
| Isomerism | 1 | 1992 | 201 | 0.010 |
Why?
|
| Sialyltransferases | 1 | 1992 | 75 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1993 | 285 | 0.010 |
Why?
|
| Thyroid Diseases | 2 | 1986 | 379 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2001 | 1624 | 0.010 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1992 | 82 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 1877 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2000 | 2036 | 0.010 |
Why?
|
| Diet | 1 | 2009 | 7937 | 0.010 |
Why?
|
| Medical Records | 1 | 1996 | 1413 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1999 | 4185 | 0.010 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 93 | 0.010 |
Why?
|
| Libido | 1 | 1990 | 121 | 0.010 |
Why?
|
| Psychotherapy | 1 | 1999 | 1642 | 0.010 |
Why?
|
| Hospitals | 1 | 2003 | 3954 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2003 | 5316 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1990 | 862 | 0.010 |
Why?
|
| Calcifediol | 1 | 1989 | 166 | 0.010 |
Why?
|
| Disabled Persons | 1 | 1998 | 1212 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1993 | 1487 | 0.000 |
Why?
|
| Erectile Dysfunction | 1 | 1990 | 461 | 0.000 |
Why?
|
| Testis | 1 | 1989 | 804 | 0.000 |
Why?
|
| Registries | 1 | 2001 | 8091 | 0.000 |
Why?
|
| Dopamine Antagonists | 1 | 1985 | 296 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1998 | 9145 | 0.000 |
Why?
|
| Kidney Tubules | 1 | 1985 | 488 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1985 | 683 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1985 | 1681 | 0.000 |
Why?
|
| Phenotype | 1 | 2000 | 16367 | 0.000 |
Why?
|
| Organ Culture Techniques | 1 | 1983 | 813 | 0.000 |
Why?
|
| Nitrogen | 1 | 1981 | 344 | 0.000 |
Why?
|
| Urea | 1 | 1981 | 450 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1987 | 2617 | 0.000 |
Why?
|